Quantitative Investment Management LLC Grows Position in Boston Scientific Corporation $BSX

Quantitative Investment Management LLC increased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 128.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 213,737 shares of the medical equipment provider’s stock after purchasing an additional 120,019 shares during the quarter. Boston Scientific accounts for approximately 1.0% of Quantitative Investment Management LLC’s portfolio, making the stock its 18th biggest position. Quantitative Investment Management LLC’s holdings in Boston Scientific were worth $9,122,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of BSX. Renaissance Group LLC acquired a new position in shares of Boston Scientific in the 4th quarter worth approximately $28,064,000. Perigon Wealth Management LLC purchased a new stake in Boston Scientific in the second quarter valued at approximately $883,000. Y Intercept Hong Kong Ltd raised its position in Boston Scientific by 148.8% in the second quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after purchasing an additional 670,060 shares during the period. Wealthfront Advisers LLC acquired a new position in Boston Scientific during the second quarter worth $3,253,000. Finally, PensionDanmark Pensionsforsikringsaktieselskab lifted its stake in Boston Scientific by 9.9% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after purchasing an additional 28,961 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BSX has been the subject of a number of research reports. Robert W. Baird set a $56.00 price objective on Boston Scientific in a research note on Thursday, July 30th. Raymond James Financial reissued an “outperform” rating and set a $57.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Canaccord Genuity Group lowered their target price on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Citigroup dropped their target price on Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Finally, Evercore set a $65.00 price target on shares of Boston Scientific in a research report on Monday, July 6th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig bought 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael F. Mahoney purchased 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 194,522 shares of company stock valued at $9,385,210 in the last quarter. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Stock Down 0.0%

Boston Scientific stock opened at $46.82 on Monday. The firm has a market capitalization of $67.85 billion, a P/E ratio of 18.96, a P/E/G ratio of 1.02 and a beta of 0.56. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The stock’s fifty day simple moving average is $46.56 and its 200-day simple moving average is $56.53.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same period last year, the business posted $0.75 earnings per share. Boston Scientific’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its board has initiated a stock buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its shares are undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.